Open AccessHERPUD1, a Member of the Endoplasmic Reticulum Protein Quality Control Mechanism, may be a Good Target for Suppressing Tumorigenesis in Breast Cancer Cells
Author(s) -
Yalçın Erzurumlu,
Yagmur Doganlar,
Hatice Kübra Doğan,
Deniz Cataklı,
Esra Aydoğdu
Publication year - 2023
Publication title -
turkish journal of pharmaceutical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.241
H-Index - 14
eISSN - 2148-6247
pISSN - 1304-530X
DOI - 10.4274/tjps.galenos.2022.71643
Subject(s) - cyclin d1 , angiogenesis , cancer research , carcinogenesis , gene silencing , cancer , cell cycle , breast cancer , biology , cell growth , cancer cell , endoplasmic reticulum , cyclin a , microbiology and biotechnology , biochemistry , genetics , gene
Breast cancer is the most frequently diagnosed cancer type and the second leading cause of cancer-related death in women. Recent studies have highlighted the importance of the endoplasmic reticulum (ER) protein quality control mechanism for the survival of many cancers. It has also been recommended as a good target for the treatment of many cancer types. Homocysteine inducible ER protein with ubiquitin-like domain 1 (HERPUD1) functions as one of the main components of ER-associated degradation, which is an ER-resident protein quality mechanism. Today, the association of HERPUD1 with breast carcinogenesis is still not fully understood. Herein, we evaluated the possibility of HERPUD1 as a potential therapeutic target for breast cancer.